STOCK TITAN

Miromatrix Medical Inc - MIRO STOCK NEWS

Welcome to our dedicated news page for Miromatrix Medical (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Miromatrix Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Miromatrix Medical's position in the market.

Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) successfully completes the tender offer to acquire Miromatrix Medical Inc. (Nasdaq: MIRO) for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to mirokidney™ by December 31, 2025. 22,876,102 shares of Miromatrix common stock were validly tendered, representing approximately 83% of the issued and outstanding shares. Merger Sub merged with and into Miromatrix, making it a wholly owned subsidiary of United Therapeutics. Shares of Miromatrix common stock ceased trading on Nasdaq, and United Therapeutics intends to cause such shares to be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced the results of the tender offer by Merger Sub, a United Therapeutics subsidiary, to acquire all outstanding shares of Miromatrix for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s mirokidney™ product by December 31, 2025. The tender offer expired with shares representing more than a majority of the issued and outstanding Miromatrix common stock validly tendered and received. The merger is expected to be completed on December 13, 2023, with Miromatrix becoming a wholly owned subsidiary of United Therapeutics and its shares delisted from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary
Miromatrix Medical Inc. (Nasdaq: MIRO) reported third quarter 2023 financial results and announced a definitive merger agreement with United Therapeutics Corporation. The company's unrestricted cash and investments totaled $16.1 million, with an operating loss of $6.6 million for the third quarter. Miromatrix has agreed to be acquired by United Therapeutics for $3.25 per share in cash at closing, with an additional $1.75 per share upon the achievement of a clinical development milestone related to their mirokidney™ product by December 31, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) has announced its definitive agreement to acquire Miromatrix Medical Inc. (Nasdaq: MIRO), a life sciences company focused on bioengineered organs. The acquisition will expand United Therapeutics' organ manufacturing programs and address the shortage of transplantable organs. The purchase price is $3.25 per share in cash at closing, with an additional $1.75 per share upon achieving a clinical development milestone. The transaction is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
216.35%
Tags
-
Rhea-AI Summary
Miromatrix Medical Inc. to present at ISODP Organ Donation Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences
-
Rhea-AI Summary
Miromatrix Medical Inc. CEO to present at 2023 Cell & Gene Meeting on the Mesa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
Rhea-AI Summary
Miromatrix Medical Inc. to present at H.C. Wainwright Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
Miromatrix Medical Inc. to present at ARM Tissue Engineering and Therapeutics Workshop on September 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences earnings
Miromatrix Medical Inc

Nasdaq:MIRO

MIRO Rankings

MIRO Stock Data

92.95M
19.61M
24.68%
22.04%
0.04%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Eden Prairie

About MIRO

miromatrix medical inc. is a life science company that has a novel and proprietary technology to remove cells from, or decellularize, organs and tissues from animal and human sources, facilitating the creation of numerous products, including the potential of fully biological transplantable human organs.